Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025
Press Releases

Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025

- Phase I Follow-Up Data Showed an Overall Survival of 29.8 Months with the Addition of CONV01-α to 177Lu-PSMA-I&T in Advanced Prostate Cancer

avatar profile Olean Times Herald

Olean Times Herald


Local & Social